Aviva Bio
Tracked across 1 events · 6 articles · First seen Sep 15, 2026 · Last active Sep 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023…
Impact: Aviva Bio is developing a next-generation testosterone product addressing breast cancer risk, targeting the women's market.
Sep 15, 2026 · 6 articles
40
Aviva Bio developing testosterone productTestosterone Therapy for...
ERGEN INTELLIGENCE
Track Aviva Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard